Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TPH1 | P17752 | 2/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5398714 | 0.90 | CTSB (0.39) | TDP1TSHRMAPTBCHEACHE | |
| SCHEMBL5385740 | 0.89 | CYP2D6 (0.36) | — | |
| SCHEMBL5384676 | 0.86 | ALDH1A1 (0.39) | BCHEACHEPOLB | |
| SCHEMBL6619568 | 0.84 | TDP1 (0.39) | TDP1TSHRPPARDPPARALMNA | |
| SCHEMBL6062807 | 0.82 | CTSS (0.37) | TDP1TSHRLMNATP53MAPT | |
| SCHEMBL6062810 | 0.82 | CTSS (0.37) | TDP1TSHRLMNATP53MAPT | |
| SCHEMBL5393849 | 0.82 | CTSK (0.36) | LMNATP53MAPT | |
| SCHEMBL6650669 | 0.81 | TDP1 (0.43) | TDP1TSHRPPARDPPARALMNA | |
| SCHEMBL6650666 | 0.81 | TDP1 (0.43) | TDP1TSHRPPARDPPARALMNA | |
| SCHEMBL6650677 | 0.81 | TDP1 (0.43) | TDP1TSHRPPARDPPARALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203138-A1 | Novel Compounds and Compositions as Cathepsin S Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-30 | — | — | US | claimed |
| US-7226921-B2 | Compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | claimed |
| US-6977256-B2 | Compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | claimed |
| US-20050267044-A1 | Novel compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | claimed |
| US-20030199506-A1 | Novel compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS INC. | 2003-10-23 | — | — | US | claimed |
| US-20070203138-A1 | Novel Compounds and Compositions as Cathepsin S Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-7226921-B2 | Compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-6977256-B2 | Compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050267044-A1 | Novel compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | disclosed |
| EP-1446392-A1 | OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20030199506-A1 | Novel compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2003042197-A1 | OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267044-A1 | Novel compounds and compositions as cathepsin S inhibitors | CTSS, CTSB, CTSE | TDP1 2886/4885TSHR 4383/4885TPH1 4550/4885 |
| US-20070203138-A1 | Novel Compounds and Compositions as Cathepsin S Inhibitors | CTSS, CTSB, CTSE | TDP1 2886/4885TSHR 4383/4885TPH1 4550/4885 |
| US-20030199506-A1 | Novel compounds and compositions as cathepsin S inhibitors | CTSS, CTSB, CTSE | TDP1 2180/4885TSHR 4422/4885TPH1 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.